Korlym’s Mechanism Of Action Complicated Cushing’s Trial Design
This article was originally published in Pharmaceutical Approvals Monthly
The standard measure of efficacy in Cushing’s syndrome – reduced cortisol levels – is not applicable to mifepristone, which blocks the biological effect of cortisol at the receptor level. Corcept needed to select clinical endpoints from among the multisystem manifestations of Cushing’s syndrome.
You may also be interested in...
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.
The latest news about products accepted into US FDA expedited review programs.